Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 398 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertrophic Clear all

Conditions: Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction, Systolic Anterior Motion
Interventions: SESAME Procedure; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Boston, Massachusetts + 5 more

Conditions: Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis, Idiopathic Non-Cirrhotic Portal Hypertension
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 100 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertrophy
Interventions: Whole egg and resistance training, Egg whites and resistance training; Dietary Supplement
Lead sponsor: Alexei Wong; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Arlington, Virginia

Conditions: Pulmonary Hypertension
Interventions: Diagnostic imaging procedures.; Other
Lead sponsor: University of Cincinnati; Other
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Prostatic Hyperplasia, Benign Prostatic Hyperplasia (BPH), Prostatism, Lower Urinary Tract Symptoms (LUTS), Prostatic Hypertrophy, Hyperplasia, Male Urogenital Diseases, Genital Diseases, Male
Interventions: Embozene Microspheres; Device
Lead sponsor: University of Virginia; Other
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hypertrophic Cardiomyopathy
Interventions: trans-right ventricular alcohol septal ablation (TRVASA); Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Technical Sucess, Freedom From Type I and III Endoleaks at 12 Months, Freedom From Stent Graft Migration at 12 Months, Freedom From Aortic Aneurysm Enlargement at 12 Months, Freedom From Aortic Aneurysm Rupture or Conversion to Open Repair at 12 Months
Interventions: Physician Modified Endografting; Device
Lead sponsor: Baystate Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Benign Prostatic Hyperplasia, Enlarged Prostate
Interventions: Tadalafil, Placebo, Finasteride; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 10
States / cities: Davis, California • Fresno, California • Laguna Hills, California + 7 more

Conditions: Children, Postoperative Pain, Tonsillar Hypertrophy, Obstructive Sleep Apnea, Chronic Tonsillitis
Interventions: Acupuncture, Sham Control; Other
Lead sponsor: Children's ENT of San Diego, Inc.; Other
Eligibility: 2 Years to 17 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: El Centro, California • San Diego, California

Conditions: Congenital Heart Defect
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 9,999,999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Peripheral Artery Disease, Coronary Disease, Diabetes and Heart Failure, Dilated Cardiomyopathy, Heart Failure, Renal Artery Stenosis, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2009
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Cardiomyopathy, Hypertrophic
Interventions: LCZ696, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Stanford, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more

Conditions: Hypertrophic Cardiomyopathy
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy, Myocardial Ischemia
Interventions: Losartan; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Myocardial Fibrosis, Hypertrophic Cardiomyopathy
Interventions: Spironolactone, Placebo; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Autoimmune Disease, Lymphatic Disease, Lymphoproliferative Disorder
Interventions: Pyrimethamine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atrial Fibrillation
Interventions: Dronedarone, Placebo (for Dronedarone); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 21 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 56
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 51 more

Conditions: Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain
Interventions: Octreotide, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypertrophic Cardiomyopathy (HCM)
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Up to 21 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Liver Cancer, Cancer of the Liver
Interventions: 4Dimensional Phase Contrast Magnetic Resonance Angiography, Portal vein embolization; Device · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Gaucher Disease
Interventions: Plant cell expressed recombinant glucocerebrosidase (prGCD); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
U.S. locations: 14
States / cities: La Jolla, California • Aurora, Colorado • Coral Springs, Florida + 11 more

Conditions: Obstructive Sleep Apnea, Enlargement of Tonsil or Adenoid
Interventions: Caffeine and sodium Benzoate 10 mg/kg IV, Caffeine and Sodium Benzoate 20 mg/kg IV, 0.9 NS Saline; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 2 Years to 12 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions: Pacritinib, Best Available Therapy; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 50
States / cities: Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 42 more

Conditions: Cardiomyopathy
Interventions: Not listed
Lead sponsor: Tenaya Therapeutics; Industry
Eligibility: 0 Years to 18 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 21
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 17 more

Search by objective public record fields.

NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices

Natural History of Noncirrhotic Portal Hypertension

Egg Consumption and Muscular Adaptations

Right Ventricular Hypertrophy and Pulmonary Hypertension: A Correlation Analysis

Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia

Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study

Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysms

A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms

Acupuncture for Tonsillectomy Pain

Signs and Symptoms Associated With Molecular Defects in Genetically Inherited Heart Disease

Evaluation of Patients With Known or Suspected Heart Disease

Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

Functional Capacity and Quality of Life Following Septal Myectomy in Patients With HCM

Long Term Effects of Enalapril and Losartan on Genetic Heart Disease

Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy

Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome

Effects of Dronedarone on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement

Octreotide in Severe Polycystic Liver Disease

Identification of Risk Factors for Arrhythmia in Children and Adolescents With Hypertrophic Cardiomyopathy

4D Phase Contrast MR: Hypertrophy in Liver Cancer

Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease

Caffeine in Children With Obstructive Sleep Apnea, Dose Response Study

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy